{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-003441","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2024-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.062033+00:00","generated_at":"2026-06-06T20:12:54.686326+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Indaptus amends bylaws to adopt universal proxy rules and exclusive federal forum","bullets":["Board adopted amended bylaws effective Jan 22, 2024, addressing universal proxy rules (Rule 14a-19 compliance).","Enhanced disclosure requirements for stockholder director nominations and business proposals.","Prohibits stockholder from submitting more director nominees than seats for election.","Requires proxy cards other than white for stockholders soliciting proxies.","Establishes federal district courts as exclusive forum for Securities Act claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-003441","json":"https://secwatch.observer/filing/0001493152-24-003441.json","markdown":"https://secwatch.observer/filing/0001493152-24-003441.md","text":"https://secwatch.observer/filing/0001493152-24-003441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224003441/0001493152-24-003441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224003441/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:12:54.686326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"716aa2f692457556b6739144c4608bbe3fbd64b6","claim":"Indaptus Therapeutics, Inc.: Amended and restated bylaws to address universal proxy rules, streamline stockholder nomination procedures, add exclusive forum provision, and make technical changes (effective 2024-01-22).","evidence_excerpt":"On January 22, 2024, the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224003441/0001493152-24-003441-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-01-22"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}